BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saeed M, Chen F, Ye J, Shi Y, Lammers T, De Geest BG, Xu ZP, Yu H. From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer. Adv Mater 2021;33:e2008094. [PMID: 34048101 DOI: 10.1002/adma.202008094] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 26.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Xie W, Lin J, Zhuo Y, Zou Z, He H, Xu Q, Tang Z, Tan H, Liu R, Deng Y, Cai S, Ye J, Wang L, Zou F, Zhong W. Untargeted metabolomics to analyze alterations in two-dimensional graphdiyne–copper nanocomposite on the metabolic reprogramming of prostate cancer. 2D Mater 2023;10:015011. [DOI: 10.1088/2053-1583/ac9e67] [Reference Citation Analysis]
2 Chen W, Sheng P, Chen Y, Liang Y, Wu S, Jia L, He X, Zhang C, Wang C, Yuan C. Hypoxia-responsive immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy for potentiating cancer immunotherapy. Chemical Engineering Journal 2023;451:138781. [DOI: 10.1016/j.cej.2022.138781] [Reference Citation Analysis]
3 Wang D, Gu W, Chen W, Zhou J, Yu L, Kook Kim B, Zhang X, Seung Kim J. Advanced nanovaccines based on engineering nanomaterials for accurately enhanced cancer immunotherapy. Coordination Chemistry Reviews 2022;472:214788. [DOI: 10.1016/j.ccr.2022.214788] [Reference Citation Analysis]
4 Zhu Y, Zhang S, Lai Y, Pan J, Chen F, Wang T, Wang F, Xu Z, Yang W, Yu H. Self‐Cooperative Prodrug Nanovesicles Migrate Immune Evasion to Potentiate Chemoradiotherapy in Head and Neck Cancer. Advanced Science 2022. [DOI: 10.1002/advs.202203263] [Reference Citation Analysis]
5 Guo HL, Xie XY, Xu M. Application of nanomaterials in combined thermal ablation and immunotherapy for liver tumors. Shijie Huaren Xiaohua Zazhi 2022; 30(19): 829-837 [DOI: 10.11569/wcjd.v30.i19.829] [Reference Citation Analysis]
6 Shu L, Huang Z, Huang Y, Wu C, Pan X. Upon a potential approach to regulate the targeting region of inhalable liposomes. Journal of Bioactive and Compatible Polymers. [DOI: 10.1177/08839115221121862] [Reference Citation Analysis]
7 He K, Xie M, Li J, He Y, Yin Y. CENPO is Associated with Immune Cell Infiltration and is a Potential Diagnostic and Prognostic Marker for Hepatocellular Carcinoma. IJGM 2022;Volume 15:7493-7510. [DOI: 10.2147/ijgm.s382234] [Reference Citation Analysis]
8 Liu H, Xie Z, Zheng M. Unprecedented Chiral Nanovaccines for Significantly Enhanced Cancer Immunotherapy. ACS Appl Mater Interfaces 2022. [PMID: 36007113 DOI: 10.1021/acsami.2c11596] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Wang B, Bai J, Tian B, Chen H, Yang Q, Chen Y, Xu J, Zhang Y, Dai H, Ma Q, Fei Z, Wang H, Xu F, Zhou X, Wang C. Genetically Engineered Hematopoietic Stem Cells Deliver TGF-β Inhibitor to Enhance Bone Metastases Immunotherapy. Adv Sci (Weinh) 2022;:e2201451. [PMID: 35948516 DOI: 10.1002/advs.202201451] [Reference Citation Analysis]
10 Ye J, Hou B, Chen F, Zhang S, Xiong M, Li T, Xu Y, Xu Z, Yu H. Bispecific prodrug nanoparticles circumventing multiple immune resistance mechanisms for promoting cancer immunotherapy. Acta Pharmaceutica Sinica B 2022;12:2695-709. [DOI: 10.1016/j.apsb.2021.09.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
11 Ye J, Hou B, Saeed M, Xu Z, Yu H. Engineering Bioinspired Nanomedicines to Mitigate the Resistance to Cancer Immunotherapy. Acc Mater Res . [DOI: 10.1021/accountsmr.2c00042] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Li F, Lai Y, Ye J, Saeed M, Dang Y, Zou Z, Chen F, Zhang W, Xu Z. Dual-targeting prodrug nanotheranostics for NIR-Ⅱ fluorescence imaging-guided photo-immunotherapy of glioblastoma. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.05.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Li JH, Huang LJ, Zhou HL, Shan YM, Chen FM, Lehto VP, Xu WJ, Luo LQ, Yu HJ. Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy. Acta Pharmacol Sin 2022. [PMID: 35484402 DOI: 10.1038/s41401-022-00910-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ansari AA, Parchur AK, Chen G. Surface modified lanthanide upconversion nanoparticles for drug delivery, cellular uptake mechanism, and current challenges in NIR-driven therapies. Coordination Chemistry Reviews 2022;457:214423. [DOI: 10.1016/j.ccr.2022.214423] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
15 Wang Y, Xie H, Wu Y, Xu S, Li Y, Li J, Xu X, Wang S, Li Y, Zhang Z. Bioinspired Lipoproteins of Furoxans-Oxaliplatin Remodel Physical Barriers in Tumor to Potentiate T-Cell Infiltration. Adv Mater 2022;34:e2110614. [PMID: 35092711 DOI: 10.1002/adma.202110614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Yan D, Wang M, Wu Q, Niu N, Li M, Song R, Rao J, Kang M, Zhang Z, Zhou F, Wang D, Tang BZ. Multimodal Imaging-Guided Photothermal Immunotherapy Based on a Versatile NIR-II Aggregation-Induced Emission Luminogen. Angew Chem Int Ed Engl 2022;:e202202614. [PMID: 35344252 DOI: 10.1002/anie.202202614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
17 Wang Y, Huo J, Li S, Huang R, Fan D, Cheng H, Wan B, Du Y, He H, Zhang G. Self-Rectifiable and Hypoxia-Assisted Chemo-Photodynamic Nanoinhibitor for Synergistic Cancer Therapy. ACS Appl Mater Interfaces 2022;14:10092-101. [PMID: 35170301 DOI: 10.1021/acsami.1c23121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zheng Y, Han Y, Sun Q, Li Z. Harnessing anti‐tumor and tumor‐tropism functions of macrophages via nanotechnology for tumor immunotherapy. Exploration. [DOI: 10.1002/exp.20210166] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 14.0] [Reference Citation Analysis]
19 Du L, He H, Xiao Z, Xiao H, An Y, Zhong H, Lin M, Meng X, Han S, Shuai X. GSH-Responsive Metal-Organic Framework for Intratumoral Release of NO and IDO Inhibitor to Enhance Antitumor Immunotherapy. Small 2022;:e2107732. [PMID: 35218310 DOI: 10.1002/smll.202107732] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
20 Xue Y, Che J, Ji X, Li Y, Xie J, Chen X. Recent advances in biomaterial-boosted adoptive cell therapy. Chem Soc Rev 2022. [PMID: 35170589 DOI: 10.1039/d1cs00786f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
21 Du Y, Zhang R, Yang J, Liu S, Zhou J, Zhao R, He F, Zhang Y, Yang P, Lin J. A “Closed‐Loop” Therapeutic Strategy Based on Mutually Reinforced Ferroptosis and Immunotherapy. Adv Funct Materials 2022;32:2111784. [DOI: 10.1002/adfm.202111784] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
22 Burkert SC, He X, Shurin GV, Nefedova Y, Kagan VE, Shurin MR, Star A. Nitrogen-Doped Carbon Nanotube Cups for Cancer Therapy. ACS Appl Nano Mater . [DOI: 10.1021/acsanm.1c03245] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Cheng H, Fan X, Ye E, Chen H, Yang J, Ke L, You M, Liu M, Zhang YW, Wu YL, Liu G, Loh XJ, Li Z. Dual Tumor Microenvironment Remodeling by Glucose-Contained Radical Copolymer for MRI-Guided Photoimmunotherapy. Adv Mater 2021;:e2107674. [PMID: 34755922 DOI: 10.1002/adma.202107674] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 18.0] [Reference Citation Analysis]
24 Zeng Z, Jiang X, Pan Z, Zhou R, Lin Z, Tang Y, Cui Y, Zhang E, Cao Z. Highly expressed centromere protein L indicates adverse survival and associates with immune infiltration in hepatocellular carcinoma. Aging (Albany NY) 2021;13:22802-29. [PMID: 34607313 DOI: 10.18632/aging.203574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Zhou F, Gao J, Tang Y, Zou Z, Jiao S, Zhou Z, Xu H, Xu ZP, Yu H, Xu Z. Engineering Chameleon Prodrug Nanovesicles to Increase Antigen Presentation and Inhibit PD-L1 Expression for Circumventing Immune Resistance of Cancer. Adv Mater 2021;33:e2102668. [PMID: 34463392 DOI: 10.1002/adma.202102668] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 15.0] [Reference Citation Analysis]
26 Song R, Li T, Ye J, Sun F, Hou B, Saeed M, Gao J, Wang Y, Zhu Q, Xu Z, Yu H. Acidity-Activatable Dynamic Nanoparticles Boosting Ferroptotic Cell Death for Immunotherapy of Cancer. Adv Mater 2021;33:e2101155. [PMID: 34170581 DOI: 10.1002/adma.202101155] [Cited by in Crossref: 48] [Cited by in F6Publishing: 60] [Article Influence: 48.0] [Reference Citation Analysis]